Riskpilot← Back to searchSign inGet full accessApoGlyx AB
ABActiveOrg 5567567085LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20081 employees
Revenue 2025
SEK 0
EBITDA margin
—
+70% vs 2024
Equity ratio
93.4%
Financial strength
Net profit 2025
SEK -337K
+60% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -211K | +70% |
| Net profit | SEK -337K | +60% |
| Total assets | SEK 14,8M | +2% |
| Equity | SEK 13,9M | +29% |
| Employees | 1 | — |
Legal name
ApoGlyx AB
Org number
5567567085
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 april 2008
Share capital
SEK 265 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Rützler, Michael Rudolf i förening med en av ledamöterna Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling och kommersialisering av läkemedel samt därmed förenlig verksamhet.
Address
Lund
Phone
+46735393913
Email
info@apoglyx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 55 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −150 | −627 | −310 | −433 | −79 | −522 | −604 | −447 | −708 | −211 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −150 | −627 | −310 | −433 | −79 | −522 | −604 | −447 | −708 | −211 |
| Net financials | — | −2 | — | — | — | — | — | — | −129 | −126 |
| Profit before tax | −150 | −628 | −310 | −433 | −80 | −522 | −604 | −447 | −836 | −337 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −150 | −628 | −310 | −433 | −80 | −522 | −604 | −447 | −836 | −337 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 757 | 4 674 | 4 968 | 5 507 | 6 963 | 13 478 | 12 425 | 12 015 | 14 480 | 14 838 |
| Equity | 4 650 | 4 022 | 4 712 | 4 279 | 7 123 | 12 621 | 12 017 | 11 570 | 10 734 | 13 860 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 200 | 0 |
| Short-term debt | 107 | 652 | 256 | 1 228 | 241 | 857 | 408 | 445 | 546 | 978 |
| Total debt | 107 | 652 | 256 | 1 228 | 241 | 857 | 408 | 445 | 3 746 | 978 |
EBITDA margin
-21100000.0%
This company
15.8%
Market median
-133544404% vs market
20162025
Equity ratio
93.4%
This company
38.2%
Market median
+145% vs market
20162025
Return on equity
-2.4%
This company
18.4%
Market median
-113% vs market
20162025
Net profit margin
-33700000.0%
This company
8.1%
Market median
-416049483% vs market
20162025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162025
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Chief Auditor | Chief Auditor | 2021 | — | — |
MR Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2026 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2026 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ApoGlyx AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Michael Rudolf Rützler | Chief Executive Officer | 0 companies |
| Karin Marie Christine Widstrand | Board of Directors | 0 companies |
| Ulf Andreas Linderoth Norlin | Board of Directors | 0 companies |
| Per Ola Kjellbom | Board of Directors | 0 companies |
| Anja Holm | Board of Directors | 0 companies |
| Helen Monika Pettersson | Board of Directors | 0 companies |
| Preben Bruun-Nyzell | Chairman | 0 companies |
| Lars Allan Grundemar | Board of Directors | 0 companies |
| Gert Roland Andersson | Board of Directors | 0 companies |
| Lars Johan Evenäs | Board of Directors | 0 companies |
| Kenneth Stokholm | Board of Directors | 0 companies |